- Tenovin-1
-
- $112.00
-
2026-07-27
- CAS:380315-80-0
- Purity: 99.44%
- Supply Ability: 10g
- TENOVIN-1
-
- $5.00
-
2019-09-04
- CAS:380315-80-0
- Min. Order: 1KG
- Purity: 99%
- Supply Ability: 1ton
|
| | TENOVIN-1 Basic information |
| Product Name: | TENOVIN-1 | | Synonyms: | CS-571;TENOVIN-1;N-[[[4-(Acetylamino)phenyl]amino]thioxomethyl]-4-(1,1-dimethylethyl)benzamide;N-[(4-acetaMidophenyl)carbaMothioyl]-4-tert-butylbenzaMide;Benzamide, N-[[[4-(acetylamino)phenyl]amino]thioxomethyl]-4-(1,1-dimethylethyl)-;N-[[[4-(Acetylamino)phenyl]amino]thioxomethyl]-4-(1,1-dimethylethyl)benzamide Tenovin 1;Tenovin 1 N-[[[4-(Acetylamino)phenyl]amino]thioxomethyl]-4-(1,1-dimethylethyl)benzamide;Tenovin-1, >=98% | | CAS: | 380315-80-0 | | MF: | C20H23N3O2S | | MW: | 369.48 | | EINECS: | 200-256-5 | | Product Categories: | Inhibitor;Inhibitors | | Mol File: | 380315-80-0.mol |  |
| | TENOVIN-1 Chemical Properties |
| Melting point | >180°C (Subl.) | | density | 1.238±0.06 g/cm3(Predicted) | | storage temp. | Sealed in dry,Room Temperature | | solubility | Soluble in DMSO (10 mg/ml with warming) | | pka | 9.09±0.70(Predicted) | | form | solid | | color | White | | Stability: | Stable for 2 years from date of purchase as supplied. Solutions in DMSO may be stored at -20°C for up to 3 months. | | InChI | 1S/C20H23N3O2S/c1-13(24)21-16-9-11-17(12-10-16)22-19(26)23-18(25)14-5-7-15(8-6-14)20(2,3)4/h5-12H,1-4H3,(H,21,24)(H2,22,23,25,26) | | InChIKey | WOWJIWFCOPZFGV-UHFFFAOYSA-N | | SMILES | S=C(Nc2ccc(cc2)NC(=O)C)NC(=O)c1ccc(cc1)C(C)(C)C |
| RIDADR | 3077 | | WGK Germany | WGK 1 | | HS Code | 29242990 | | Storage Class | 11 - Combustible Solids |
| | TENOVIN-1 Usage And Synthesis |
| Description | Tenovin-1 is a small molecule activator of p53 transcriptional activity. At 10 μM, it elevates p53 expression in MCF-7 cells within two hours of treatment and longer-term exposure significantly decreases the growth of BL2 Burkitt’s lymphoma and ARN8 melanoma cells. Functioning upstream of p53, tenovin-1 acts by inhibiting the deacetylase activity of purified human SIRT1 and SIRT2, members of NAD+-dependent class III histone deacetylases that belong to the sirtuin family. While tenovin-1 demonstrates low genotoxicity, the compound has poor water solubility, which limits its uses in vivo. | | Uses | Tenovin 1 is a sirtuin inhibitor. | | Definition | ChEBI: N-[(4-acetamidoanilino)-sulfanylidenemethyl]-4-tert-butylbenzamide is a member of thioureas. | | Biological Activity | p53 activator that protects against MDM2-mediated p53 degradation. Elevates levels of p53 and p21 CIP/WAF1 and induces expression from an endogenous p53-dependent promoter. Exhibits potent antiproliferative activity in vitro . | | in vivo | Tenovin-1 (92 mg/kg, i.p.) reduces growth of tumors in SCID mice derived from BL2 cells or ARN8 cells[5]. | | IC 50 | MDM-2/p53; DHODH; Sirtuin | | References | [1] SONIA LAIN. Discovery, in vivo activity, and mechanism of action of a small-molecule p53 activator.[J]. Cancer Cell, 2008, 13 5: 454-463. DOI:10.1016/j.ccr.2008.03.004
[2] J SONNEMANN. p53-dependent and p53-independent anticancer effects of different histone deacetylase inhibitors[J]. British Journal of Cancer, 2013, 110 3: 656-667. DOI:10.1038/bjc.2013.742
[3] MINAKSHI NIHAL Gary S W Nihal Ahmad. SIRT1 is upregulated in cutaneous T-cell lymphoma, and its inhibition induces growth arrest and apoptosis.[J]. Cell Cycle, 2014, 13 4: 632-640. DOI:10.4161/cc.27523
[4] MELISSA J. WILKING . SIRT1 deacetylase is overexpressed in human melanoma and its small molecule inhibition imparts anti-proliferative response via p53 activation[J]. Archives of biochemistry and biophysics, 2014, 563: Pages 94-100. DOI:10.1016/j.abb.2014.04.001
[5] CHRISTIAN MARX. The sirtuin 1/2 inhibitor tenovin-1 induces a nonlinear apoptosis-inducing factor-dependent cell death in a p53 null Ewing’s sarcoma cell line.[J]. Investigational New Drugs, 2018: 396-406. DOI:10.1007/s10637-017-0541-1
[6] MINJI BANG. Tenovin-1 Induces Senescence and Decreases Wound-Healing Activity in Cultured Rat Primary Astrocytes.[J]. Biomolecules & Therapeutics, 2019, 27 3: 283-289. DOI:10.4062/biomolther.2018.107 |
| | TENOVIN-1 Preparation Products And Raw materials |
|